FTH Faeth Therapeutics (FTH) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001829802
C-suite buying · 2Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
38
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $62.0K priced
What the filings say about FTH
Insiders, 180 days
+$1.2M net bought
2 buyers
Planned sales (Form 144), 90 days
$3.6M
1 notice
Faeth Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Faeth Therapeutics, Inc. insiders bought a net $1.2M of stock across 23 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Jun 30, 2026.
- +31.6% median (+29.3% mean) 90-day return after 6 previous buys.
- The trade is 9.5% of the 46,088 shares held after it.
- 1 other insider bought within 30 days.
- 38 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer STEPHENSON BRIAN C bought about $103.0K of FTH on Jul 1, 2026; 1 other insider bought within 30 days and 38 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Jun 30, 2026.
- +31.6% median (+29.3% mean) 90-day return after 6 previous buys.
- The trade is 1.3% of the 46,688 shares held after it.
- 1 other insider bought within 30 days.
- 38 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer STEPHENSON BRIAN C bought about $14.5K of FTH on Jul 1, 2026; 1 other insider bought within 30 days and 38 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Jun 29, 2026.
- +36.1% median (+33.0% mean) 90-day return after 5 previous buys.
- The trade is 5.3% of the 35,795 shares held after it.
- 1 other insider bought within 30 days.
- 38 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer STEPHENSON BRIAN C bought about $43.8K of FTH on Jun 30, 2026; 1 other insider bought within 30 days and 38 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Jun 29, 2026.
- +36.1% median (+33.0% mean) 90-day return after 5 previous buys.
- The trade is 4.4% of the 37,433 shares held after it.
- 1 other insider bought within 30 days.
- 38 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer STEPHENSON BRIAN C bought about $39.1K of FTH on Jun 30, 2026; 1 other insider bought within 30 days and 38 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Jun 29, 2026.
- +36.1% median (+33.0% mean) 90-day return after 5 previous buys.
- The trade is 10.2% of the 41,688 shares held after it.
- 1 other insider bought within 30 days.
- 38 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer STEPHENSON BRIAN C bought about $106.3K of FTH on Jun 30, 2026; 1 other insider bought within 30 days and 38 funds added in the latest 13F quarter.23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.2M over 180 days
more than 90% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
38 funds bought in last quarter
below 58% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.2% of the float short (float per yahoo 2026-10-26) · 3.6 days to cover · settled 2026-09-30
more than 64% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 23 in the prior 90
Why it matters
The absence is the signal: 23 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch FTH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+60.9%12M
Insider buyForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FTH: institutional holders (13F)
13F holdings, latest reported quarter
2,020,103 sh
$50.5M
1,444,039 sh
$36.1M
1,286,411 sh
$32.2M
1,042,198 sh
$26.1M
722,020 sh
$18.1M
Congress trades in FTH
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
FTH planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Cambrian BioPharma Inc
Filed 2026-08-11
$3.6M
FTH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Franklin Biotechnology Discovery Fund
$4.9M position · as of 2026-07-31
0.4%
iShares Micro-Cap ETF
$79.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$5.2K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$252.9K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$96.7K position · as of 2026-05-31
0.0%
Total Stock Market Index Trust
$1.0K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Phase 2
1 active
2
Not applicable
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.2M bought by insiders over 180 days, 38 funds added last quarter, $3.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
FTH financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM FTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM FTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$33.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM FTH
| FY Dec 2025 | -$20.5M |
| FY Dec 2024 | -$24.8M |
| FY Dec 2023 | -$32.2M |
| FY Dec 2022 | -$39.3M |
| FY Dec 2021 | -$32.3M |
| Jun 2026 | -$15.7M |
| Mar 2026 | -$10.7M |
| Dec 2025 | -$3.9M |
| Sep 2025 | -$3.6M |
| Jun 2025 | -$5.9M |
| Mar 2025 | -$7.1M |
| Dec 2024 | -$5.8M |
| Sep 2024 | -$5.5M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2021-06-30 (60 months older than the period end); equity 2026-06-30
Debt to equity FTH
| FY Dec 2025 | 0.03x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.01x |
| FY Dec 2022 | 0.01x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | n/a |
| Dec 2025 | 0.03x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.02x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-59.71x
TTM operating cash flow over long-term debt only, 2021-06-30 (60 months older than the period end)
Cash flow to debt FTH
| FY Dec 2025 | -36.07x |
| FY Dec 2024 | -43.51x |
| FY Dec 2023 | -56.48x |
| FY Dec 2022 | -68.83x |
| FY Dec 2021 | -53.37x |
| Jun 2026 | -59.71x |
| Mar 2026 | -42.49x |
| Dec 2025 | -36.07x |
| Sep 2025 | -39.47x |
| Jun 2025 | -42.80x |
| Mar 2025 | -42.59x |
| Dec 2024 | -43.51x |
| Sep 2024 | -44.16x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-195.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FTH
| FY Dec 2025 | -74.0% |
| FY Dec 2024 | -58.4% |
| FY Dec 2023 | -40.5% |
| FY Dec 2022 | -38.9% |
| FY Dec 2021 | -81.7% |
| Jun 2026 | -195.3% |
| Mar 2026 | n/a |
| Dec 2025 | -74.0% |
| Sep 2025 | -70.2% |
| Jun 2025 | -67.5% |
| Mar 2025 | -64.2% |
| Dec 2024 | -58.4% |
| Sep 2024 | -51.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-176.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FTH
| FY Dec 2025 | -61.8% |
| FY Dec 2024 | -50.4% |
| FY Dec 2023 | -35.4% |
| FY Dec 2022 | -35.8% |
| FY Dec 2021 | -42.1% |
| Jun 2026 | -176.9% |
| Mar 2026 | -151.4% |
| Dec 2025 | -61.8% |
| Sep 2025 | -59.7% |
| Jun 2025 | -58.6% |
| Mar 2025 | -55.3% |
| Dec 2024 | -50.4% |
| Sep 2024 | -44.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital FTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-191.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FTH
| FY Dec 2025 | -76.1% |
| FY Dec 2024 | -60.0% |
| FY Dec 2023 | -41.6% |
| FY Dec 2022 | -39.0% |
| FY Dec 2021 | -45.5% |
| Jun 2026 | -191.5% |
| Mar 2026 | -165.6% |
| Dec 2025 | -76.1% |
| Sep 2025 | -72.2% |
| Jun 2025 | -69.1% |
| Mar 2025 | -65.8% |
| Dec 2024 | -60.0% |
| Sep 2024 | -52.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing FTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$408.6M
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term debt only, 2021-06-30 (60 months older than the period end), minus cash 2026-06-30
Enterprise value FTH
| FY Dec 2025 | $5.4M |
| FY Dec 2024 | $237.1M |
| FY Dec 2023 | $333.5M |
| FY Dec 2022 | $898.2M |
| FY Dec 2021 | $3.5B |
| Jun 2026 | $7.2M |
| Mar 2026 | -$109.5M |
| Dec 2025 | $5.4M |
| Sep 2025 | $1.9M |
| Jun 2025 | $204.3M |
| Mar 2025 | $189.3M |
| Dec 2024 | $237.1M |
| Sep 2024 | $282.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-7.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield FTH
| FY Dec 2025 | -152.1% |
| FY Dec 2024 | -10.1% |
| FY Dec 2023 | -9.3% |
| FY Dec 2022 | -4.3% |
| FY Dec 2021 | -0.9% |
| Jun 2026 | -100.9% |
| Mar 2026 | -57.1% |
| Dec 2025 | -152.1% |
| Sep 2025 | -187.9% |
| Jun 2025 | -11.2% |
| Mar 2025 | -12.2% |
| Dec 2024 | -10.1% |
| Sep 2024 | -8.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing FTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$22.3M | -$32.6M | -$37.1M | -$50.2M |
| Net income | -$21.1M | -$30.2M | -$34.1M | -$48.6M |
| EPS (diluted) | -16.72 | -24.01 | -1.22 | -1.58 |
| Operating cash flow | -$20.5M | -$24.7M | -$32.0M | -$39.0M |
| Cash | $8.7M | $10.0M | $13.0M | $17.8M |
| Buybacks | n/a | n/a | $10.4M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
FTH Stock Sonar score 5/7 axes
Find similar shapesCompareFTH ranks highest on insider conviction (85th percentile) and financial health (45th), and lowest on profitability (14th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
FTH filings, in plain words
Are Faeth Therapeutics insiders buying or selling FTH?
In the 180 days to 2026-10-28, Faeth Therapeutics insiders were net buyers, a net $1.2M across purchases and sales reported on Form 4, by 2 buyers.
Are there planned insider sales of FTH?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $3.6M of stock; the latest, by Cambrian BioPharma Inc, was filed 2026-08-11.
Read the full summary
In the 180 days to 2026-10-28, Faeth Therapeutics insiders were net buyers of FTH, a net $1.2M across purchases and sales reported on Form 4 by 2 buyers. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $3.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
